ArticleFrontiers in oncology2026
Exploiting machine-learning models with DCE-MRI radiomics for breast cancer molecular subtyping.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a heterogeneous disease, and accurate preoperative identification of molecular subtypes is essential for guiding individualized treatment and prognostic evaluation. However, histopathological assessment, the current gold standard, is invasive and limited by intratumoral heterogeneity, underscoring the need for reliable noninvasive alternatives. Radiomics based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has shown promise for molecular subtype prediction; nevertheless, the optimal radiomic features for automated molecular classification remain to be fully elucidated. To address this gap, this study aims to identify optimal DCE-MRI radiomic features and to develop radiomics-based machine learning models for predicting breast cancer molecular subtypes. Specifically, regions of interest were manually delineated on DCE-MRI images for feature extraction, followed by feature selection to identify the most informative radiomic parameters. Four machine learning classifiers (RF, SVM, LR, GBDT) were then constructed to predict five molecular subtypes of breast cancer. The experimental results demonstrate that the optimized DCE-MRI-based radiomics model effectively predicts breast cancer molecular subtypes. In particular, the gradient boosting decision tree (GBDT) model combined with rigorous feature selection shows high predictive performance, highlighting its strong potential for noninvasive, accurate, and clinically applicable molecular classification of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.